Free Trial

EU: Possible virus drug approval 'before the summer'

LONDON (AP) — The European Medicines Agency predicted that there could be licensed drugs to treat the new coronavirus in the next few months and that a vaccine might even be approved in early 2021, in a “best-case scenario.”

Dr. Marco Cavaleri, who heads the European regulator’s vaccines department, told a media briefing on Thursday that approving medicines to treat COVID-19 might be possible “before the summer,” citing ongoing clinical trials. Recent early results for the drug remdesivir suggested it could help patients recover from the coronavirus faster, although longer-term data is still needed to confirm any benefit.

Although it typically takes years to develop a vaccine, Cavaleri said that if some of the shots already being tested prove to be effective, they could be licensed as early as the beginning of next year.

Cavaleri cautioned, however, that many experimental vaccines never make it to the end and that there are often delays.

“But we can see the possibility that if everything goes as planned, vaccines could be approved a year from now,” he said.

More than 140 heads of states and health experts, including South African President Cyril Ramaphosa, Pakistani Prime Minister Imran Khan and Nobel laureate Joseph Stiglitz issued an appeal Thursday calling on all countries to unite behind a “people’s vaccine” against COVID-19, to ensure any effective treatments and vaccines be available globally to anyone who needs them, for free.

At the moment, there are about a dozen vaccine candidates being tested in China, Britain, Germany and the U.S. The World Health Organization has estimated it could take about 12 to 18 months for an effective vaccine to be found.

While some experts have proposed dropping the requirement for large-scale advanced clinical trials altogether, Cavaleri said that wasn't currently being considered.

“Our current thinking is all vaccines under development should undergo large phase 3 trials to establish what is the level of protection,” he said.

But he acknowledged that could change if the situation worsened.

“Things may evolve as the pandemic will evolve and we will see if we need to do something else,” Cavaleri said.

Some officials have warned that a vaccine might never be found; previous attempts to develop a vaccine against related coronaviruses like SARS and MERS have all failed. But Cavleri was optimistic an immunization against COVID-19 would eventually be discovered, as there are various technologies being tried globally.

“I think it's a bit early to say, but we have good reason to be sufficiently optimistic that at the end of the day, some vaccines will make it,” he said.

___

Follow AP pandemic coverage at http://apnews.com/VirusOutbreak and https://apnews.com/UnderstandingtheOutbreak

Where Should You Invest $1,000 Right Now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines